209 related articles for article (PubMed ID: 31487061)
1. EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.
Adamik J; Pulugulla SH; Zhang P; Sun Q; Lontos K; Macar DA; Auron PE; Galson DL
J Bone Miner Res; 2020 Jan; 35(1):181-195. PubMed ID: 31487061
[TBL] [Abstract][Full Text] [Related]
2. Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model.
Caviness PC; Gai D; Lazarenko OP; Blackburn ML; Zhan F; Chen JR
FASEB J; 2023 Jul; 37(7):e23019. PubMed ID: 37272906
[TBL] [Abstract][Full Text] [Related]
3. Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8.
Fang C; Qiao Y; Mun SH; Lee MJ; Murata K; Bae S; Zhao B; Park-Min KH; Ivashkiv LB
J Immunol; 2016 Jun; 196(11):4452-4456. PubMed ID: 27183582
[TBL] [Abstract][Full Text] [Related]
4. DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis.
Cao X; He W; Rong K; Xu S; Chen Z; Liang Y; Han S; Zhou Y; Yang X; Ma H; Qin A; Zhao J
Stem Cell Res Ther; 2021 Dec; 12(1):605. PubMed ID: 34930462
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.
Jarome TJ; Perez GA; Hauser RM; Hatch KM; Lubin FD
J Neurosci; 2018 Aug; 38(35):7635-7648. PubMed ID: 30030400
[TBL] [Abstract][Full Text] [Related]
6. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
7. Activating transcription factor 4 regulates osteoclast differentiation in mice.
Cao H; Yu S; Yao Z; Galson DL; Jiang Y; Zhang X; Fan J; Lu B; Guan Y; Luo M; Lai Y; Zhu Y; Kurihara N; Patrene K; Roodman GD; Xiao G
J Clin Invest; 2010 Aug; 120(8):2755-66. PubMed ID: 20628199
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB.
Smink JJ; Bégay V; Schoenmaker T; Sterneck E; de Vries TJ; Leutz A
EMBO J; 2009 Jun; 28(12):1769-81. PubMed ID: 19440205
[TBL] [Abstract][Full Text] [Related]
9. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
11. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.
Smink JJ; Tunn PU; Leutz A
J Mol Med (Berl); 2012 Jan; 90(1):25-30. PubMed ID: 22071989
[TBL] [Abstract][Full Text] [Related]
13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.
Shanmugarajan S; Youssef RF; Pati P; Ries WL; Rao DS; Reddy SV
J Cell Biochem; 2008 Jul; 104(4):1500-8. PubMed ID: 18348201
[TBL] [Abstract][Full Text] [Related]
16. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Ezh2 redistributes bivalent domains within transcriptional regulators associated with WNT and Hedgehog pathways in osteoblasts.
Carrasco ME; Thaler R; Nardocci G; Dudakovic A; van Wijnen AJ
J Biol Chem; 2023 Sep; 299(9):105155. PubMed ID: 37572850
[TBL] [Abstract][Full Text] [Related]
18. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
[TBL] [Abstract][Full Text] [Related]
20. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
